Brain-Computer Interface (BCI), as a frontier core technology enabling direct interconnection between the human brain and external terminals, has been listed as a national strategic future industry, marking the industry’s official shift toward commercialization and on-the-ground implementation.

VCBeat conducted a specialized survey of nearly 200 domestic BCI-related enterprises. It screened companies from multiple dimensions including financing strength, patent portfolio, certified products, cross-border partnerships and core team capabilities. By deconstructing the industrial structure based on core products and business lines, VCBeat has compiled a comprehensive BCI industry map.

This map clearly presents company numbers and technological focuses across all sub-sectors, and compiles corporate profiles, financing track records and the latest industry updates.

VCBeat has built in-depth connections with all enterprises on the map, offering exclusive cooperation channels and providing full-spectrum, authoritative data to support industrial planning, trend analysis, business collaboration and investment decision-making.

Junshi Biosciences Voluntarily Discloses NMPA Approval of New Indication for Toripalimab in Combination with Disitamab Vedotin as First-Line Treatment for HER2-Expressing Urothelial Carcinoma

Junshi Biosciences

RemeGen